Research ArticleArticle
Open Access
Similarity of Response to Biologics Between Elderly-onset Rheumatoid Arthritis (EORA) and Non-EORA Elderly Patients: From the FIRST Registry
Sae Ochi, Fumitaka Mizoguchi, Kazuhisa Nakano and Yoshiya Tanaka
The Journal of Rheumatology February 2021, jrheum.201135; DOI: https://doi.org/10.3899/jrheum.201135
Sae Ochi
S. Ochi, PhD, Department of Laboratory Medicine, The Jikei University School of Medicine, Tokyo, and the First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu; F. Mizoguchi, PhD, Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo; K. Nakano, PhD, The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu; Y. Tanaka, PhD, Professor, The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan. F. Mizoguchi passed away on November 17, 2020. YT has received speaking fees and/or honoraria from Daiichi Sankyo, Eli Lilly, Novartis, YL Biologics, BMS, Eisai, Chugai, AbbVie, Astellas, Pfizer, Sanofi, Asahi Kasei, GSK, Mitsubishi Tanabe Pharma, Gilead, and Janssen; and has received research grants from Mitsubishi Tanabe Pharma, Chugai, AbbVie, Takeda, UCB, Daiichi Sankyo, Eisai. SO has received speaking fees from Mitsubishi Tanabe Pharma and Janssen Pharmaceutical. FM has received consulting fees, research funding and/or speaking fees from AbbVie, Asahi Kasei Pharma, Astellas Pharma, BMS, Chugai Pharmaceutical, Daiichi Sankyo Company, Eisai, Eli Lilly, ImmunoForge, Janssen Pharmaceutical, Japan Blood Products Organization, Mitsubishi Tanabe Pharma, Novartis Pharma Japan, Ono Pharmaceutical, Pfizer, Sanofi, Takeda Pharmaceutical Company, Teijin, and UCB Japan. KN has received grants and personal fees from Mitsubishi Tanabe Pharma, Eisai, Eli Lilly; and personal fees from BMS, Sanofi, Chugai, Pfizer, Takeda, and AbbVie. Address correspondence to Dr. Y. Tanaka, the First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Iseigaoka 1-1, Kitakyshu City, Fukuoka 807-8555, Japan. Email: tanaka@med.uoeh-u.ac.jp. Accepted for publication January 25, 2021.
Fumitaka Mizoguchi
S. Ochi, PhD, Department of Laboratory Medicine, The Jikei University School of Medicine, Tokyo, and the First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu; F. Mizoguchi, PhD, Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo; K. Nakano, PhD, The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu; Y. Tanaka, PhD, Professor, The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan. F. Mizoguchi passed away on November 17, 2020. YT has received speaking fees and/or honoraria from Daiichi Sankyo, Eli Lilly, Novartis, YL Biologics, BMS, Eisai, Chugai, AbbVie, Astellas, Pfizer, Sanofi, Asahi Kasei, GSK, Mitsubishi Tanabe Pharma, Gilead, and Janssen; and has received research grants from Mitsubishi Tanabe Pharma, Chugai, AbbVie, Takeda, UCB, Daiichi Sankyo, Eisai. SO has received speaking fees from Mitsubishi Tanabe Pharma and Janssen Pharmaceutical. FM has received consulting fees, research funding and/or speaking fees from AbbVie, Asahi Kasei Pharma, Astellas Pharma, BMS, Chugai Pharmaceutical, Daiichi Sankyo Company, Eisai, Eli Lilly, ImmunoForge, Janssen Pharmaceutical, Japan Blood Products Organization, Mitsubishi Tanabe Pharma, Novartis Pharma Japan, Ono Pharmaceutical, Pfizer, Sanofi, Takeda Pharmaceutical Company, Teijin, and UCB Japan. KN has received grants and personal fees from Mitsubishi Tanabe Pharma, Eisai, Eli Lilly; and personal fees from BMS, Sanofi, Chugai, Pfizer, Takeda, and AbbVie. Address correspondence to Dr. Y. Tanaka, the First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Iseigaoka 1-1, Kitakyshu City, Fukuoka 807-8555, Japan. Email: tanaka@med.uoeh-u.ac.jp. Accepted for publication January 25, 2021.
Kazuhisa Nakano
S. Ochi, PhD, Department of Laboratory Medicine, The Jikei University School of Medicine, Tokyo, and the First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu; F. Mizoguchi, PhD, Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo; K. Nakano, PhD, The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu; Y. Tanaka, PhD, Professor, The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan. F. Mizoguchi passed away on November 17, 2020. YT has received speaking fees and/or honoraria from Daiichi Sankyo, Eli Lilly, Novartis, YL Biologics, BMS, Eisai, Chugai, AbbVie, Astellas, Pfizer, Sanofi, Asahi Kasei, GSK, Mitsubishi Tanabe Pharma, Gilead, and Janssen; and has received research grants from Mitsubishi Tanabe Pharma, Chugai, AbbVie, Takeda, UCB, Daiichi Sankyo, Eisai. SO has received speaking fees from Mitsubishi Tanabe Pharma and Janssen Pharmaceutical. FM has received consulting fees, research funding and/or speaking fees from AbbVie, Asahi Kasei Pharma, Astellas Pharma, BMS, Chugai Pharmaceutical, Daiichi Sankyo Company, Eisai, Eli Lilly, ImmunoForge, Janssen Pharmaceutical, Japan Blood Products Organization, Mitsubishi Tanabe Pharma, Novartis Pharma Japan, Ono Pharmaceutical, Pfizer, Sanofi, Takeda Pharmaceutical Company, Teijin, and UCB Japan. KN has received grants and personal fees from Mitsubishi Tanabe Pharma, Eisai, Eli Lilly; and personal fees from BMS, Sanofi, Chugai, Pfizer, Takeda, and AbbVie. Address correspondence to Dr. Y. Tanaka, the First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Iseigaoka 1-1, Kitakyshu City, Fukuoka 807-8555, Japan. Email: tanaka@med.uoeh-u.ac.jp. Accepted for publication January 25, 2021.
Yoshiya Tanaka
S. Ochi, PhD, Department of Laboratory Medicine, The Jikei University School of Medicine, Tokyo, and the First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu; F. Mizoguchi, PhD, Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo; K. Nakano, PhD, The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu; Y. Tanaka, PhD, Professor, The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan. F. Mizoguchi passed away on November 17, 2020. YT has received speaking fees and/or honoraria from Daiichi Sankyo, Eli Lilly, Novartis, YL Biologics, BMS, Eisai, Chugai, AbbVie, Astellas, Pfizer, Sanofi, Asahi Kasei, GSK, Mitsubishi Tanabe Pharma, Gilead, and Janssen; and has received research grants from Mitsubishi Tanabe Pharma, Chugai, AbbVie, Takeda, UCB, Daiichi Sankyo, Eisai. SO has received speaking fees from Mitsubishi Tanabe Pharma and Janssen Pharmaceutical. FM has received consulting fees, research funding and/or speaking fees from AbbVie, Asahi Kasei Pharma, Astellas Pharma, BMS, Chugai Pharmaceutical, Daiichi Sankyo Company, Eisai, Eli Lilly, ImmunoForge, Janssen Pharmaceutical, Japan Blood Products Organization, Mitsubishi Tanabe Pharma, Novartis Pharma Japan, Ono Pharmaceutical, Pfizer, Sanofi, Takeda Pharmaceutical Company, Teijin, and UCB Japan. KN has received grants and personal fees from Mitsubishi Tanabe Pharma, Eisai, Eli Lilly; and personal fees from BMS, Sanofi, Chugai, Pfizer, Takeda, and AbbVie. Address correspondence to Dr. Y. Tanaka, the First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Iseigaoka 1-1, Kitakyshu City, Fukuoka 807-8555, Japan. Email: tanaka@med.uoeh-u.ac.jp. Accepted for publication January 25, 2021.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Similarity of Response to Biologics Between Elderly-onset Rheumatoid Arthritis (EORA) and Non-EORA Elderly Patients: From the FIRST Registry
Sae Ochi, Fumitaka Mizoguchi, Kazuhisa Nakano, Yoshiya Tanaka
The Journal of Rheumatology Feb 2021, jrheum.201135; DOI: 10.3899/jrheum.201135